Unapproved hydrocodone ordered off the market by FDA
FDA orders unapproved hydrocodone makers to cease marketing
As part of its crackdown on marketing of unapproved drugs, the FDA has ordered manufacturers of hydrocodone products that have not undergone agency review to cease further production and distribution. The action is enforceable under the agency's Compliance Policy Guide, which was published in June 2006 and highlights the risks associated with such products. The FDA said it has received reports of medication errors associated with formulary changes and similarity of names of the unapproved hydrocodone, and it is particularly concerned with the fact that some products list dosages for children as young as two years despite the fact that no hydrocodone cough suppressant has been established as safe and effective for children younger than six. Companies must cease manufacture and distribution of products currently labeled for use in children under the age of six years by Oct. 31. Any other unapproved hydrocodone-containing products must stop production by Dec. 31 and cease further shipment by March 31, 2008.
Click here to see more articles from Drug Topics Daily News.
To go to the Drug Topics homepage, click here.
FDA Approves Lebrikizumab-lbkz for Moderate-to-Severe Atopic Dermatitis
September 16th 2024Lebrikizumab-lbks is a targeted treatment that addresses the root cause of atopic dermatitis; by reducing inflammation throughout the body, it can help alleviate the dry, itchy, and irritated skin that often characterizes the condition.
